Company: HROW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001641172-25-000925
Chunk: 213

Company: HARROW, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1A
Chunk 213
---
 drug candidates, and we are in the process of assessing certain of our other assets in order to determine whether
to pursue their development or commercialization. In addition, we expect to consider the acquisition of additional intellectual property
rights or other assets in the future. Once we decide to pursue a potential drug candidate, we develop a commercialization strategy for
it, which may include pursuing FDA approval of the drug candidate. We may incorrectly assess the risks and benefits of the commercialization
options or we may not pursue a commercialization strategy that proves to be successful. If we are unable to successfully commercialize
one or more of our drug products and drug candidates, our operating results would be adversely affected. Even if we are able to successfully
sell one or more drug products and drug candidates, we may never recoup our investment in acquiring or developing the drug products and
drug candidates. Our failure to identify and expend our resources and technologies with commercial potential and execute an effective
commercialization strategy for each of our drug products and drug candidates would negatively impact the long-term profitability of our
business.

We may need additional capital in order to
continue operating our business and to operate as a going concern, and such additional funds may not be available when needed, on acceptable
terms, or at all.

We may need significant additional
capital to execute our business plan, execute on future acquisitions and fund our proposed business operations. Additionally, our plans
may change or the estimates of our operating expenses and working capital requirements could be inaccurate, we may pursue acquisitions
of FDA-approved products, drug candidates, pharmacies or other strategic transactions that involve large expenditures, or we may experience
growth more quickly or on a larger scale than we expect, any of which may result in the depletion of capital resources more rapidly than
anticipated and could require us to seek additional financing earlier than we expect to support our operations.

In January 2026 debt in the
amount of $107,500,000 principal amount becomes due under the Oaktree Loan. The maturity of this debt obligation without a
refinancing event could raise substantial doubt about the Company’s ability to continue as a going concern. While the Company
is currently in discussions with its current senior secured lender and other potential lenders about refinancing and management
believes it is probable that the Company will be able to refinance such amount based on the Company’s collateral strength and expected cash flows
from operations, there can be no assurance that the Company
completes a refinancing on terms acceptable to it, or